Leish-111f, a recombinant polyprotein vaccine that protects against visceral leishmaniasis by elicitation of CD4+ T cells

Infection and Immunity

Volumn 75, Issue 9, 2007, Pages 4648-4654

  Coler, Rhea N ^a   Goto, Yasuyuki ^a   Bogatzki, Lisa ^a   Raman, Vanitha ^a   Reed, Steven G ^a  

^a INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; CYTOKINE; GAMMA INTERFERON; INITIATION FACTOR; INTERLEUKIN 2; LEISH 111F PROTEIN; PHOSPHORYL LIPID A; PROTOZOAL PROTEIN; RECOMBINANT PROTEIN; RECOMBINANT VACCINE; STRESS INDUCIBLE PROTEIN 1; THIOL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; EMULSION; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNITY; LEISHMANIA INFANTUM; MOUSE; NONHUMAN; PRIORITY JOURNAL; VISCERAL LEISHMANIASIS;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CRICETINAE; FEMALE; HEAT-SHOCK PROTEINS; LEISHMANIASIS, VISCERAL; LIPID A; LYMPHOCYTE ACTIVATION; MESOCRICETUS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PEPTIDE INITIATION FACTORS; PEROXIDASES; POLYPROTEINS; PROTOZOAN PROTEINS; PROTOZOAN VACCINES; VACCINES, SYNTHETIC;

EID: 34547870667     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.00394-07     Document Type: Article

References (50)

1. Basu, R., et al. 2005. Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1-and Th2-like responses in visceral leishmaniasis. J. Immunol. 174:7160-7171.
2. Bebars, M. A., et al. 2000. An experimental vaccine providing heterologous protection for Leishmania species in murine model. J. Egypt. Soc. Parasitol. 30:137-156.
3. Berberich, C., et al. 2003. Dendritic cell (DC)-based protection against an intracellular pathogen is dependent upon DC-derived IL-12 and can be induced by molecularly defined antigens. J. Immunol. 170:3171-3179.
4. Borges, M. M., et al. 2001. Potent stimulation of the innate immune system by a Leishmania braziliensis recombinant protein. Infect. Immun. 69:5270-5277.
5. Campbell, K., H. Diao, J. Ji, and L. Soong. 2003. DNA immunization with the gene encoding P4 nuclease of Leishmania amazonensis protects mice against cutaneous leishmaniasis. Infect. Immun. 71:6270-6278.
6. Coler, R. N., et al. 1998. Molecular cloning and immunologic reactivity of a novel low molecular mass antigen of Mycobacterium tuberculosis. J. Immunol. 161:2356-2364.
7. Coler, R. N., et al. 2002. Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis. Infect. Immun. 70:4215-4225.
8. Coler, R. N., and S. G. Reed. 2005. Second-generation vaccines against leishmaniasis. Trends Parasitol. 21:244-249.
9. Coler, R. N., and S. G. Reed. 2005. Second-generation vaccines against leishmaniasis. Trends Parasitol. 21:244-249.
10. Desjeux, P. 2004. Leishmaniasis: current situation and new perspectives. Comp. Immunol. Microbiol. Infect. Dis. 27:305-318.
11. Dumonteil, E., et al. 2000. Comparative study of DNA vaccines encoding various antigens against Leishmania mexicana. Dev. Biol. (Basel) 104:135-141.
12. Dumonteil, E., R. S. Maria Jesus, E. O. Javier, and G. M. Maria del Rosario. 2003. DNA vaccines induce partial protection against Leishmania mexicana. Vaccine 21:2161-2168.
13. Erickson, L. D., et al. 2002. Short-circuiting long-lived humoral immunity by the heightened engagement of CD40. J. Clin. Investig. 109:613-620.
14. Ghosh, A., W. W. Zhang, and G. Matlashewski. 2001. Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections. Vaccine 20:59-66.
15. Green, S. J., et al. 1994. Nitric oxide: cytokine-regulation of nitric oxide in host resistance to intracellular pathogens. Immunol. Lett. 43:87-94.
16. Liew, F. Y., C. Parkinson, S. Millott, A. Severn, and M. Carrier. 1990. Tumour necrosis factor (TNF alpha) in leishmaniasis. I. TNF alpha mediates host protection against cutaneous leishmaniasis. Immunology 69:570-573.
17. Liew, F. Y., S. Millott, C. Parkinson, R. M. Palmer, and S. Moncada. 1990. Macrophage killing of Leishmania parasite in vivo is mediated by nitric oxide from L-arginine. J. Immunol. 144:4794-4797.
18. Liew, F. Y., Y. Li, and S. Millott. 1990. Tumour necrosis factor (TNF-alpha) in leishmaniasis. II. TNF-alpha-induced macrophage leishmanicidal activity is mediated by nitric oxide from L-arginine. Immunology 71:556-559.
19. Melby, P. C., J. Yang, W. Zhao, L. E. Perez, and J. Cheng. 2001. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. Infect. Immun. 69:4719-4725.
20. Murphy, M. L., U. Wille, E. N. Villegas, C. A. Hunter, and J. P. Farrell. 2001. IL-10 mediates susceptibility to Leishmania donovani infection. Eur. J. Immunol. 31:2848-2856.
21. Murray, H. W. 1994. Interferon-gamma and host antimicrobial defense: current and future clinical applications. Am. J. Med. 97:459-467.
22. Murray, H. W. 2001. Clinical and experimental advances in treatment of visceral leishmaniasis. Antimicrob. Agents Chemother. 45:2185-2197.
23. Murray, H. W., and C. F. Nathan. 1999. Macrophage microbicidal mechanisms in vivo: reactive nitrogen versus oxygen intermediates in the killing of intracellular visceral Leishmania donovani. J. Exp. Med. 189:741-746.
24. Murray, H. W., et al. 1987. Experimental visceral leishmaniasis: production of interleukin 2 and interferon-gamma, tissue immune reaction, and response to treatment with interleukin 2 and interferon-gamma. J. Immunol. 138:2290-2297.
25. Murray, H. W., G. D. Miralles, M. Y. Stoeckle, and D. F. McDermott. 1993. Role and effect of IL-2 in experimental visceral leishmaniasis. J. Immunol. 151:929-938.
26. Murray, H. W., A. Jungbluth, E. Ritter, C. Montelibano, and M. W. Marino. 2000. Visceral leishmaniasis in mice devoid of tumor necrosis factor and response to treatment. Infect. Immun. 68:6289-6293.
27. Murray, H. W., J. Hariprashad, B. Aguero, T. Arakawa, and H. Yeganegi. 1995. Antimicrobial response of a T cell-deficient host to cytokine therapy: effect of interferon-gamma in experimental visceral leishmaniasis in nude mice. J. Infect. Dis. 171:1309-1316.
28. Niedbala, W., X. Q. Wei, D. Piedrafita, D. Xu, and F. Y. Liew. 1999. Effects of nitric oxide on the induction and differentiation of Th1 cells. Eur. J. Immunol. 29:2498-2505.
29. Olobo, J. O., et al. 1995. Vaccination of vervet monkeys against cutaneous leishmaniosis using recombinant Leishmania "major surface glycoprotein" (gp63). Vet. Parasitol. 60:199-212.
30. Perez-Victoria, F. J., S. Castanys, and F. Gamarro. 2003. Leishmania donovani resistance to miltefosine involves a defective inward translocation of the drug. Antimicrob. Agents Chemother. 47:2397-2403.
31. Persing, D. H., et al. 2002. Taking toll: lipid A mimetics as adjuvants and immunomodulators. Trends Microbiol. 10:S32-S37.
32. Probst, P., et al. 1997. A Leishmania protein that modulates interleukin (IL)-12, IL-10 and tumor necrosis factor-alpha production and expression of B7-1 in human monocyte-derived antigen-presenting cells. Eur. J. Immunol. 27:2634-2642.
33. Rachamim, N., and C. L. Jaffe. 1993. Pure protein from Leishmania donovani protects mice against both cutaneous and visceral leishmaniasis. J. Immunol. 150:2322-2331.
34. Rafati, S., et al. 2005. Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum. Vaccine. 23:3716-3725.
35. Rafati, S., A. A. Baba, M. Bakhshayesh, and M. Vafa. 2000. Vaccination of BALB/c mice with Leishmania major amastigote-specific cysteine proteinase. Clin. Exp. Immunol. 120:134-138.
36. Rafati, S., F. Zahedifard, and F. Nazgouee. 2006. Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis. Vaccine. 24:2169-2175.
37. Roberts, M. T., C. B. Stober, A. N. McKenzie, and J. M. Blackwell. 2005. Interleukin-4 (IL-4) and IL-10 collude in vaccine failure for novel exacerbatory antigens in murine Leishmania major infection. Infect. Immun. 73:7620-7628.
38. Sjolander, A., T. M. Baldwin, J. M. Curtis, K. L. Bengtsson, and E. Handman.1998. Vaccination with recombinant Parasite Surface Antigen 2 from Leishmania major induces a Th1 type of immune response but does not protect against infection. Vaccine 16:2077-2084.
39. Sjolander, A., T. M. Baldwin, J. M. Curtis, and E. E. Handman. 1998. Induction of a Th1 immune response and simultaneous lack of activation of a Th2 response are required for generation of immunity to leishmaniasis. J. Immunol. 160:3949-3957.
40. Skeiky, Y. A., et al. 1995. A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin 12. J. Exp. Med. 181:1527-1537.
41. Skeiky, Y. A., et al. 1998. LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile. J. Immunol. 161:6171-6179.
42. Skeiky, Y. A., et al. 2001. Development of a multi-subunit tandemly linked recombinant polyprotein vaccine for leishmaniasis, abstr. 13. Second International Congress on Leishmania and Leishmaniasis (WorldLeishII), Crete, Greece.
43. Skeiky, Y. A., et al. 2002. Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant. Vaccine 20:3292-3303.
44. Slifka, M. K., and R. Ahmed. 1998. B cell responses and immune memory. Dev. Biol. Stand. 95:105-115.
45. Squires, K. E., et al. 1989. Experimental visceral leishmaniasis: role of endogenous IFN-gamma in host defense and tissue granulomatous response. J. Immunol. 143:4244-4249.
46. Stager, S., D. F. Smith, and P. M. Kaye. 2000. Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis. J. Immunol. 165:7064-7071.
47. Sundar, S., et al. 2000. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin. Infect. Dis. 31:1104-1107.
48. Webb, J. R., et al. 1998. Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family. Infect. Immun. 66:3279-3289.
49. Webb, J. R., A. Campos-Neto, Y. A. Skeiky, and S. G. Reed. 1997. Molecular characterization of the heat-inducible LmSTI1 protein of Leishmania major. Mol. Biochem. Parasitol. 89:179-193.
50. Webb, J. R., D. Kaufmann, A. Campos-Neto, and S. G. Reed. 1996. Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis. J. Immunol. 157:5034-5041.